Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer.

Faust SM, Bell P, Zhu Y, Sanmiguel J, Wilson JM.

Mol Ther. 2013 Dec;21(12):2227-35. doi: 10.1038/mt.2013.94. Epub 2013 Oct 15.

2.

Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity.

Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, Byrne BJ, Terhorst C, Herzog RW.

PLoS One. 2009 Aug 4;4(8):e6376. doi: 10.1371/journal.pone.0006376.

3.

BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver.

Breous E, Somanathan S, Wilson JM.

Mol Ther. 2010 Apr;18(4):766-74. doi: 10.1038/mt.2009.301. Epub 2010 Jan 12.

4.

Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.

Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K.

J Virol. 2001 Jan;75(1):269-77.

5.

Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins.

Mays LE, Vandenberghe LH, Xiao R, Bell P, Nam HJ, Agbandje-McKenna M, Wilson JM.

J Immunol. 2009 May 15;182(10):6051-60. doi: 10.4049/jimmunol.0803965.

6.

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW.

Blood. 2007 Aug 15;110(4):1132-40. Epub 2007 Apr 16.

7.

AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells.

Mays LE, Wang L, Lin J, Bell P, Crawford A, Wherry EJ, Wilson JM.

Mol Ther. 2014 Jan;22(1):28-41. doi: 10.1038/mt.2013.134. Epub 2013 Jun 19.

8.

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, Arruda VR, High KA, Herzog RW.

J Clin Invest. 2003 May;111(9):1347-56.

9.

AAV-mediated liver-directed gene therapy.

Sands MS.

Methods Mol Biol. 2011;807:141-57. doi: 10.1007/978-1-61779-370-7_6.

10.

Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.

Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, Kemper AR, Clay TM, Koeberl DD.

Hum Gene Ther. 2012 May;23(5):460-72. doi: 10.1089/hum.2011.063. Epub 2012 Mar 29.

11.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2007 Oct;7(5):316-24. Review.

PMID:
17979678
12.

Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.

Barker SE, Broderick CA, Robbie SJ, Duran Y, Natkunarajah M, Buch P, Balaggan KS, MacLaren RE, Bainbridge JW, Smith AJ, Ali RR.

J Gene Med. 2009 Jun;11(6):486-97. doi: 10.1002/jgm.1327.

13.

CpG-depleted adeno-associated virus vectors evade immune detection.

Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, Wilson JM.

J Clin Invest. 2013 Jul;123(7):2994-3001. doi: 10.1172/JCI68205. Epub 2013 Jun 17.

14.

Pseudotyped adeno-associated viral vectors for gene transfer in dermal fibroblasts: implications for wound-healing applications.

Balaji S, King A, Dhamija Y, Le LD, Shaaban AF, Crombleholme TM, Keswani SG.

J Surg Res. 2013 Sep;184(1):691-8. doi: 10.1016/j.jss.2013.03.051. Epub 2013 Apr 3.

15.

AAV as an immunogen.

Vandenberghe LH, Wilson JM.

Curr Gene Ther. 2007 Oct;7(5):325-33. Review.

PMID:
17979679
16.

The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW.

Blood. 2011 Jun 16;117(24):6459-68. doi: 10.1182/blood-2010-10-314518. Epub 2011 Apr 7.

17.

Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.

Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA.

Mol Med. 1997 Dec;3(12):813-25.

18.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2011 Aug;11(4):321-30. Review.

PMID:
21557723
19.

Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.

Li H, Murphy SL, Giles-Davis W, Edmonson S, Xiang Z, Li Y, Lasaro MO, High KA, Ertl HC.

Mol Ther. 2007 Apr;15(4):792-800. Epub 2007 Jan 23.

PMID:
17245353
20.

Complement is an essential component of the immune response to adeno-associated virus vectors.

Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, Bartlett JS, Muruve DA.

J Virol. 2008 Mar;82(6):2727-40. doi: 10.1128/JVI.01990-07. Epub 2008 Jan 16.

Items per page

Supplemental Content

Write to the Help Desk